What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist

Palatnik-de-Sousa, Clarisa B.

doi:10.3389/fimmu.2020.02173

Cited by 8 publications

(5 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incomplete viral inactivation may not be discarded, and every batch needs to be checked [2]. The development of antibody disease enhancement (ADE) syndrome due to non-neutralizing antibodies may be a risk which, in the COVID-19 scenario, can increase lung pathology [3]. Furthermore, there was a need for quickly available, massively produced vaccines.…”

Section: Commercially Available Covid-19 Vaccinesmentioning

confidence: 99%

“…Seventy-seven percent of these subjects developed ITP after receiving the first dose of the vaccine, while 23% developed it after the second one. The median (IQR) platelet count was 3 × 10 9 /L [1-9], at a median (IQR) of eight days after vaccination [3][4][5][6][7][8][9][10][11][12][13]. Nevertheless, about 90% of subjects responded to the usual first-line treatments [42].…”

Section: Covid-19 Covid-19 Vaccination and Itpmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Vaccines and Autoimmune Hematologic Disorders

et al. 2022

View full text Add to dashboard Cite

Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible.

show abstract

Section: Commercially Available Covid-19 Vaccinesmentioning

confidence: 99%

Section: Covid-19 Covid-19 Vaccination and Itpmentioning

confidence: 99%

COVID-19 Vaccines and Autoimmune Hematologic Disorders

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Hence, validation of each batch is necessary to confirm complete inactivation of recruited pathogens. The other concern related to inactivated vaccines is the possibility of antibody disease enhancement (ADE) syndrome that can be attributed to the production of non-neutralizing antibodies and can result in increased lung pathology [9]. Another vaccine platform, the protein-based vaccines, are of great use, since they beneficially induce immune responses against viral infections [10,11].…”

Section: Introductionmentioning

confidence: 99%

A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines

Ghasemiyeh

Mohammadi-Samani

Firouzabadi

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

“…Traditional and conventional vaccine development is based on Pasteur principles that consist of isolation, inactivation, and injection of non-virulent pathogenic microbes or part of the microbe into the host [130]. Conventional vaccines are vital pharmacological products, but production and development are expensive, not only economically; they also require much time.…”

Section: Discussionmentioning

confidence: 99%

Designing a Recombinant Vaccine against Providencia rettgeri Using Immunoinformatics Approach

et al. 2022

View full text Add to dashboard Cite

Antibiotic resistance (AR) is the resistance mechanism pattern in bacteria that evolves over some time, thus protecting the bacteria against antibiotics. AR is due to bacterial evolution to make itself fit to changing environmental conditions in a quest for survival of the fittest. AR has emerged due to the misuse and overuse of antimicrobial drugs, and few antibiotics are now left to deal with these superbug infections. To combat AR, vaccination is an effective method, used either therapeutically or prophylactically. In the current study, an in silico approach was applied for the design of multi-epitope-based vaccines against Providencia rettgeri, a major cause of traveler’s diarrhea. A total of six proteins: fimbrial protein, flagellar hook protein (FlgE), flagellar basal body L-ring protein (FlgH), flagellar hook-basal body complex protein (FliE), flagellar basal body P-ring formation protein (FlgA), and Gram-negative pili assembly chaperone domain proteins, were considered as vaccine targets and were utilized for B- and T-cell epitope prediction. The predicted epitopes were assessed for allergenicity, antigenicity, virulence, toxicity, and solubility. Moreover, filtered epitopes were utilized in multi-epitope vaccine construction. The predicted epitopes were joined with each other through specific GPGPG linkers and were joined with cholera toxin B subunit adjuvant via another EAAAK linker in order to enhance the efficacy of the designed vaccine. Docking studies of the designed vaccine construct were performed with MHC-I (PDB ID: 1I1Y), MHC-II (1KG0), and TLR-4 (4G8A). Findings of the docking study were validated through molecular dynamic simulations, which confirmed that the designed vaccine showed strong interactions with the immune receptors, and that the epitopes were exposed to the host immune system for proper recognition and processing. Additionally, binding free energies were estimated, which highlighted both electrostatic energy and van der Waals forces to make the complexes stable. Briefly, findings of the current study are promising and may help experimental vaccinologists to formulate a novel multi-epitope vaccine against P. rettgeri.

show abstract

What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist

Cited by 8 publications

References 55 publications

COVID-19 Vaccines and Autoimmune Hematologic Disorders

COVID-19 Vaccines and Autoimmune Hematologic Disorders

A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines

Designing a Recombinant Vaccine against Providencia rettgeri Using Immunoinformatics Approach

Contact Info

Product

Resources

About